The EPIC-CAD trial, recently published in The New England Journal of Medicine, evaluated the efficacy and safety of edoxaban monotherapy compared to dual antithrombotic therapy in patients with stable coronary artery disease (CAD) and high-risk atrial fibrillation (AF). This open-label, … Read More
Blog
MATTERHORN Trial Summary: Mitral Valve Repair vs. Surgery in Secondary MR
The MATTERHORN trial, published in The New England Journal of Medicine, investigates the efficacy of transcatheter repair (M-TEER) versus surgical mitral-valve repair for secondary mitral regurgitation (MR) in patients with heart failure. This randomized controlled trial included 208 patients, equally … Read More
40 Landmark Clinical Trials That Shaped COVID-19 Therapeutic Options and Outcomes
The COVID-19 pandemic triggered an unprecedented surge in clinical research, leading to thousands of studies aimed at understanding, managing, and ultimately controlling the virus. As healthcare systems worldwide faced the immense challenge of treating patients, researchers raced against time to … Read More
SOURCE Trial: Sorafenib in Portal Vein Tumor Thrombus
Here’s the extracted information from the provided visual abstract: SOURCE Adjuvant Transarterial Chemoembolization With Sorafenib for Portal Vein Tumor Thrombus Study Design: Objective: Participants: Intervention Groups: Primary Outcome: Secondary Outcomes: Conclusion: Citation: This summary captures the key points from the … Read More
SABATO Trial: Oral Antibiotics for Staph Aureus
Here’s the extracted information from the provided visual abstract: SABATO Efficacy and Safety of an Early Oral Switch in Low-risk Staphylococcus aureus Bloodstream Infection Study Design: Objective: Participants: Intervention Groups: Primary Outcome: Secondary Outcome: Conclusion: Citation: This summary captures the … Read More
OPT-BIRISK Trial: Clopidogrel Monotherapy in High Risk ACS
Trial Title: OPT-BIRISKStudy Type: Multicenter, double-blind, randomized trial Objective: To determine if extended P2Y12 inhibitor monotherapy with clopidogrel is superior to ongoing dual antiplatelet therapy (DAPT) with aspirin and clopidogrel after 9 to 12 months of DAPT after PCI in … Read More
CheckMate 77T Trial: Nivolumab in Lung Cancer
CheckMate 77TPerioperative Nivolumab in Resectable Lung Cancer Design: Objective: Patients: Inclusion criteria: Exclusion criteria: Comparison: Primary Outcome: Secondary Outcomes: Conclusion: Reference: This data highlights the key points of the CheckMate 77T trial, comparing the outcomes of perioperative nivolumab combined with … Read More
SEQUOIA-HCM Trial: Aficamten in HCM
SEQUOIA-HCMAficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy Design: Objective: Patients: Inclusion criteria: Exclusion criteria: Comparison: Primary Outcome: Secondary Outcomes: Conclusion: Reference: This data highlights the key points of the SEQUOIA-HCM trial, comparing the outcomes of aficamten versus placebo in patients with … Read More
STOPDAPT-3 Trial: Prasugrel Monotherapy after PCI
STOPDAPT-3 TrialShort and Optimal Duration of Dual Antiplatelet Therapy After Everolimus-Eluting Cobalt-Chromium Stent-3 Design: Objective: Patients: Inclusion criteria: Exclusion criteria: Comparison: Primary Outcomes: Secondary Outcomes: Conclusion: Reference: This data highlights the key points of the STOPDAPT-3 trial, comparing the outcomes … Read More
NOTUS Trial: Dupilumab in COPD
NOTUS TRIAL Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation A double-blind, placebo-controlled, randomized trial Objective:To assess the efficacy and safety of dupilumab in patients with moderate to severe COPD and evidence of type 2 inflammation. 935 … Read More